Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Tarveda Therapeutics

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Apr 25, 2022 2:20pm

113 Views

Post# 34629739

RE:RE:RE:RE:RE:RE:RE:Tarveda Therapeutics

Thanks for all this. It's clearly an important issue and one that they've likely understood from the beginning. We'll only really know once the program moves further along and releases data that can aid in understanding it. Once again, treatment "relative" to the normal standard of doxetaxol is what will be important --if they can get more drug in, safely. The standard already incorporates a chunk of the chemo spreading throughout every organ in the body.

One thing I recall from two other colorectal/sortilin papers is that CRC is one of the cancers where the overexpression level is closer to the 40% of cases versus cancers like melanoma, TNBC that are closer to the 90% of patients overexpressing. So CRC has always looked a little less "robust" in that differential.

At this point, all we can go by is what Marsolais and Believeau have repeated a few times to the market --that research has shown there is not a lot of sortilin overexpressed except in the tumor microenvironment (doesn't mean there isn't any elsewhere), and that off target toxicity "should" be fairly limited. Once again, the relevant comparison would be how is the safety/efficacy versus other chemo programs. We'll just have to wait and see if the human data is like the lab data. I don't think we can expect perfection around this question, just that it doesn't rise to a level to preclude moving this along clinically to the next step.

jeffm34 wrote:
The amount of off target accumulation of TH1902 will likely be higher than those therapeutics that targeted NTSR1. You can see the expression of sortilin(NTSR3) is higher in the cancer cells but also much higher in non cancer cells.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464404/

The proportion of cancer tissue which stained positively for NTSR1 (H-score > 0) was significantly higher than the proportion of normal epithelium which expressed NTSR1 (70.7% vs 10.7% respectively, p < 0.01, Fisher’s exact test). Similarly, the proportion of CRC tissue which stained positively for NTSR3 was significantly higher than normal epithelium (96.5% vs 80.4% respectively, p < 0.01, Fisher’s exact test).